Skip to content
Sign in
Artwork for OncoPharm
OncoPharm · Thursday · 16 min

PARPi's & ARPi's

This episode looks at the combination of PARP inhibitors in combination with androgen receptor pathway inhibitors (ARPi) for untreated advanced prostate cancer. BRCA2 sensitivity > BRCA 1 commentary: https://doi.org/10.1200/JCO.20.02246 Methylphenidate for fatigue in hematologic cancers: https://doi.org/10.1200/JCO-26-00578 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

0:00-16:43
Play in

transcript

No transcript — this publisher did not publish one.

show notes

This episode looks at the combination of PARP inhibitors in combination with androgen receptor pathway inhibitors (ARPi) for untreated advanced prostate cancer.

BRCA2 sensitivity > BRCA 1 commentary: https://doi.org/10.1200/JCO.20.02246

Methylphenidate for fatigue in hematologic cancers: https://doi.org/10.1200/JCO-26-00578

Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

more episodes

All episodes